Sanat Chattopadhyay is executive vice president and president, Merck Manufacturing Division. He has responsibility for the company’s worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products.
A proven leader in the biopharmaceutical industry, Sanat joined Merck in November 2009 as senior vice president of global vaccines and sterile manufacturing operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its vaccine business. Under Sanat’s leadership, Merck is currently executing significant expansion of its biologics and vaccines manufacturing capacity to reach more patients around the globe.
Before joining Merck, he served as senior vice president, technical operations and product supply, for Wyeth Pharmaceuticals, with responsibility for product supply, process development and operational excellence. Previously, he worked at Aventis and its predecessor companies as senior vice president, industrial operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific.
A graduate chemical engineer from Jadavpur University and post-graduate industrial engineer from NITIE, India, Sanat is widely travelled, having lived with his family in five countries across three continents.
What is Sanat Chattopadhyay's net worth?
The estimated net worth of Sanat Chattopadhyay is at least $2.98 million as of January 9th, 2023. Mr. Chattopadhyay owns 29,500 shares of Merck & Co., Inc. stock worth more than $2,975,075 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Chattopadhyay may own. Additionally, Mr. Chattopadhyay receives an annual salary of $2,490,000.00 as Insider at Merck & Co., Inc.. Learn More about Sanat Chattopadhyay's net worth.
How old is Sanat Chattopadhyay?
What is Sanat Chattopadhyay's salary?
As the Insider of Merck & Co., Inc., Mr. Chattopadhyay earns $2,490,000.00 per year. There are 4 executives that earn more than Mr. Chattopadhyay. The highest earning executive at Merck & Co., Inc. is Mr. Robert M. Davis J.D., Chairman, President & CEO, who commands a salary of $5,570,000.00 per year. Learn More on Sanat Chattopadhyay's salary.
How do I contact Sanat Chattopadhyay?
Has Sanat Chattopadhyay been buying or selling shares of Merck & Co., Inc.?
Sanat Chattopadhyay has not been actively trading shares of Merck & Co., Inc. during the last ninety days. Most recently, Sanat Chattopadhyay sold 134,055 shares of the business's stock in a transaction on Thursday, April 13th. The shares were sold at an average price of $115.07, for a transaction totalling $15,425,708.85. Learn More on Sanat Chattopadhyay's trading history.
Who are Merck & Co., Inc.'s active insiders?
Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), Wendell Weeks (Director), and David Williams (Executive vice president, chief information & digital officer). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?
During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 2,833 shares worth more than $250,012.25. During the last year, insiders at the sold shares 3 times. They sold a total of 15,237 shares worth more than $1,282,329.74. The most recent insider tranaction occured on November, 3rd when EVP David Michael Williams sold 8,614 shares worth more than $720,044.26. Insiders at Merck & Co., Inc. own 0.1% of the company.
Learn More about insider trades at Merck & Co., Inc.. Information on this page was last updated on 11/3/2025.
